Entrada Therapeutics, Inc.
TRDA
$8.09
-$0.24-2.88%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 91.10% | -79.33% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 91.10% | -79.33% | |||
| Cost of Revenue | 6.88% | -2.43% | |||
| Gross Profit | 134.16% | -118.65% | |||
| SG&A Expenses | -1.12% | 7.96% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.94% | -0.10% | |||
| Operating Income | 72.91% | -140.54% | |||
| Income Before Tax | 95.35% | -127.50% | |||
| Income Tax Expenses | -0.54% | -167.44% | |||
| Earnings from Continuing Operations | 108.06% | -125.50% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 108.06% | -125.50% | |||
| EBIT | 72.91% | -140.54% | |||
| EBITDA | 76.47% | -138.14% | |||
| EPS Basic | 108.02% | -121.45% | |||
| Normalized Basic EPS | 95.38% | -123.14% | |||
| EPS Diluted | 105.86% | -122.58% | |||
| Normalized Diluted EPS | 95.62% | -124.04% | |||
| Average Basic Shares Outstanding | 0.52% | 18.87% | |||
| Average Diluted Shares Outstanding | 5.96% | 14.43% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||